Predicting hemophagocytic lymphohistiocytosis in adults after a donor stem cell transplant
Studies whether routine blood tests can flag hemophagocytic lymphohistiocytosis early in adults after donor transplant.
Key facts
- Who runs it
- Peking University People's Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Hemophagocytic Lymphohistiocytosis After Allogeneic Stem Cell Transplantation
- Status
- Recruiting
- People taking part
- 10,000 people, planned
- Started
- 19 Oct 2026
- Expected to end
- 31 Dec 2029
- Type of study
- Observational, 3 groups
- Record updated
- 29 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults having their first allogeneic hematopoietic stem cell transplant (stem cells from a donor) at a participating center in China. It studies a severe inflammatory complication called HLH after transplant.
- Age
- 18 years or older at the first allogeneic hematopoietic stem cell transplant.
- Sex
- All sexes can join.
- Disease stage
- People having their first allogeneic hematopoietic stem cell transplant at a participating center during the study period.
- Earlier treatment
- People who had an allogeneic hematopoietic stem cell transplant before cannot join.
Main reasons for not taking part
- Transplant using the person's own cells (autologous), or a transplant that is not a stem cell transplant
- HLH diagnosed before the transplant, or a transplant done mainly to treat HLH
- A previous allogeneic hematopoietic stem cell transplant
- Identity, transplant date or key outcome information cannot be checked
- Refusing to take part or to allow use of clinical information
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Age 18 years or older at first allogeneic hematopoietic stem cell transplantation; First allogeneic hematopoietic stem cell transplantation performed at a participating center within the study period; Verifiable transplantation date and basic clinical information. Written informed consent from the participant or legally authorized representative for prospective participation. Retrospective records are used under the applicable ethics-approved consent or waiver procedures
Who cannot take part
- Autologous transplantation or transplantation other than hematopoietic stem cell transplantation; HLH diagnosed before transplantation, or transplantation performed primarily for HLH; Previous allogeneic hematopoietic stem cell transplantation. Patient identity, transplantation date, or key outcome information cannot be verified; Explicit refusal to participate or to permit the use of clinical information for this study
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Hemophagocytic lymphohistiocytosis (HLH) is a severe inflammatory complication that can occur after allogeneic hematopoietic stem cell transplantation. Its signs can overlap with those of infection and other transplant complications, making early recognition difficult. This study will examine whether changes in routine blood tests and clinical information can help identify patients who may develop HLH during the following seven days.
Read full original descriptionShow less
The study will combine a review of existing medical records with prospective follow-up at participating hospitals in China. Approximately 20,000 adults undergoing their first allogeneic transplantation will be included, with approximately 400 post-transplant HLH cases expected. Historical records will be used to develop the prediction model. Data from independent centers and prospectively enrolled patients will be used to validate the model.
Participants will be followed for one year after transplantation. Those who develop HLH during that year will also be followed for 90 days after HLH onset. The study will describe HLH occurrence, associated factors, treatments, and survival. All tests and treatments will remain part of routine care. No additional research samples or laboratory tests will be required, and model predictions will not be used to guide treatment.
The 3 groups in the trial
- Retrospective cohort
Patients whose first visit to our institution and the termination of follow-up both occurred before the opening of this study will contribute to the retrospective cohort.
- Prospective cohort
Patients whose first visit to our institution occur after the opening of this study will contribute to the prospective cohort.
- Retrospective/Prospective cohort
Patients whose first visit to our institution occurred before the opening of this study and whose follow-up will terminate after the opening of this study will contribute to the ambispective cohort.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Hemophagocytic Lymphohistiocytosis After Hematopoietic Stem Cell Transplantation: A Multicenter Ambispective Longitudinal Cohort Study
- Plain-language title
- Predicting hemophagocytic lymphohistiocytosis in adults after a donor stem cell transplantGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 29 October 2026